Literature DB >> 17021388

Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.

Mauricette Brocco1, Anne Dekeyne, Mariusz Papp, Mark J Millan.   

Abstract

The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17021388     DOI: 10.1097/01.fbp.0000236267.41806.5b

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  9 in total

Review 1.  Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Authors:  Horrick Sharma; Soumava Santra; Aloke Dutta
Journal:  Future Med Chem       Date:  2015-11-30       Impact factor: 3.808

2.  Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain.

Authors:  Olga Chernoloz; Mostafa El Mansari; Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2012-02       Impact factor: 6.186

3.  L-menthol exhibits antidepressive-like effects mediated by the modification of 5-HTergic, GABAergic and DAergic systems.

Authors:  Weidong Wang; Yuanyuan Jiang; Enbo Cai; Bingchen Li; Yan Zhao; Hongyan Zhu; Lianxue Zhang; Yugang Gao
Journal:  Cogn Neurodyn       Date:  2018-12-11       Impact factor: 5.082

4.  Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats.

Authors:  Kouhei Kitagawa; Yoshihisa Kitamura; Toshiaki Miyazaki; Junya Miyaoka; Hiromu Kawasaki; Masato Asanuma; Toshiaki Sendo; Yutaka Gomita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-03-10       Impact factor: 3.000

Review 5.  Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

6.  Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study.

Authors:  Tomohiro Kobayashi; Etsuko Hayashi; Midori Shimamura; Mine Kinoshita; Niall P Murphy
Journal:  Psychopharmacology (Berl)       Date:  2008-02-15       Impact factor: 4.530

Review 7.  The effect of increased serotonergic neurotransmission on aggression: a critical meta-analytical review of preclinical studies.

Authors:  Maria Carrillo; Lesley A Ricci; Glen A Coppersmith; Richard H Melloni
Journal:  Psychopharmacology (Berl)       Date:  2009-04-30       Impact factor: 4.530

8.  S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.

Authors:  Anne Dekeyne; Clotilde Mannoury la Cour; Alain Gobert; Mauricette Brocco; Françoise Lejeune; Florence Serres; Trevor Sharp; Annie Daszuta; Amélie Soumier; Mariusz Papp; Jean-Michel Rivet; Gunnar Flik; Thomas I Cremers; Olivier Muller; Gilbert Lavielle; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2008-06-04       Impact factor: 4.530

9.  Chronic Piromelatine Treatment Alleviates Anxiety, Depressive Responses and Abnormal Hypothalamic-Pituitary-Adrenal Axis Activity in Prenatally Stressed Male and Female Rats.

Authors:  Natasha Ivanova; Zlatina Nenchovska; Milena Atanasova; Moshe Laudon; Rumyana Mitreva; Jana Tchekalarova
Journal:  Cell Mol Neurobiol       Date:  2021-05-18       Impact factor: 4.231

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.